➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKesson
Mallinckrodt
Medtronic
Boehringer Ingelheim

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,642,608

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,642,608 protect, and when does it expire?

Patent 8,642,608 protects CAPRELSA and is included in one NDA.

This patent has sixty patent family members in thirty-three countries.

Summary for Patent: 8,642,608
Title:Quinazoline derivatives as VEGF inhibitors
Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from one of the following three groups: 1) C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. ##STR00001##
Inventor(s): Thomas; Andrew Peter (Macclesfield, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield, GB), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:12/761,105
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,642,608

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No   Start Trial   Start Trial FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE   Start Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes   Start Trial   Start Trial FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,642,608

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99402759Nov 5, 1999
99402877Nov 19, 1999

International Family Members for US Patent 8,642,608

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033499   Start Trial
Austria 330954   Start Trial
Austria 398120   Start Trial
Australia 1288601   Start Trial
Australia 769222   Start Trial
Bulgaria 106659   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
AstraZeneca
Colorcon
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.